


Supplementary data 1

Expression of MMP-13 in HACs in the Figure 2b




Expression of β -actin in HACs in the Figure 2b






Supplementary data 2



Supplementary data 2 (continued)




Supplementary data 3(a)

Expression of pAMPK, tAMPK and β-actin in BACs in the Figure 3a


pAMPK 50-37-25-15-10**tAMPK** 50-37-25-15-10**β-actin** IL-1β

GSK101 Compound C Expression of pNFκB, tNFκB and β-actin in BACs in the Figure 3a




Supplementary data 3(b)

Expression of pAMPK, tAMPK and β -actin in BACs in the Figure 3b





Expression of pNFkB, tNFkB and β -actin in BACs in the Figure 3b




Supplementary data 4

Expression of MMP-13 in HACs in the Figure 4c








Expression of β -actin in HACs in the Figure 4c







IL-1β GSK101 STO-609

IL-1β

GSK101

STO-609

Supplementary data 1. Original membranes of MMP-13 and β -actin of Western blot analysis of Figure 2b in the manuscript using HACs from three patients.*Co-treated with STO-609. †Co-treated with other agents which were not effective. HAC: human articular chondrocyte.

Supplementary data 2. Three replicates of explant culture of bovine articular cartilage tissue in Safranin O/Fast Green staining on day 7 in each group in Figure 2d. A substantial amount of proteoglycans was lost from explants treated with IL-1 β , while this effect was almost completely rescued by co-treatment with IL-1 β and GSK101.

Supplementary data 3. Original membranes of pAMPK and pNF κ B of Western blot analysis of Figure 3 in the manuscript using BACs treated with IL-1 β , GSK101 and (a) Compound C and (b) STO-609. BAC: bovine articular chondrocyte; p: phospho-; t: total-.

Supplementary data 4. Original membranes of MMP-13 of Western blot analysis of Figure 4c in the manuscript using HACs from three patients. HAC: human articular chondrocyte.